Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

BACKGROUND: The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of therapeutic approaches. To this end, a prospective phase II trial of neoadjuvant docetaxel (D) and complete androgen blockade (CAB) was carried out in high-risk PC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Mellado, B, Font, A, Alcaraz, A, Aparicio, L A, Veiga, F J G, Areal, J, Gallardo, E, Hannaoui, N, Lorenzo, J R M, Sousa, A, Fernandez, P L, Gascon, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768456/
https://www.ncbi.nlm.nih.gov/pubmed/19755998
http://dx.doi.org/10.1038/sj.bjc.6605320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768456/
https://www.ncbi.nlm.nih.gov/pubmed/19755998
http://dx.doi.org/10.1038/sj.bjc.6605320

Ejemplares similares